

**EXHIBIT A-5**  
**STATEMENT OF RESEARCH**

This Statement of Research is made part of that certain Material Transfer Agreement (“*Agreement*”) between iTheragnostics, Inc., a Delaware corporation, and the undersigned identified as “Recipient.”

<b>Quantity</b>	As described below in fees
<b>Research</b>	As more fully described in Appendix 1 to Appendix A-5
<b>Research Scientist</b>	Paola Caroli paola.caroli@irst.emr.it Valentina Di Iorio - valentina.diiorio@irst.emr.it

**Fees**

<b>Original Material</b>	<b>Amount</b>	<b>Fee in USD</b>
FAP1-46 precursor, GMP	50 x 50 ug vial	\$130.00 per vial x 50 = \$6,500 + \$150.00 per shipment

**Payment.**

Within thirty (30) days following the Effective Date, Recipient shall pay to Provider the Fee as compensation for the production of the Original Material. In the event Provider fails to provide the Quantity of Original Material within ninety (90) days following the Effective Date, Provider shall refund Recipient the amount of the Fee paid by Recipient. Following Provider’s delivery of the Quantity of Original Material to Recipient, the amount of the Fee paid by Recipient shall be non-refundable.

<b>Provider: iTheragnostics, Inc.</b>	<b>Recipient:</b>
By <u>SHERLY MOSESSIAN</u> <small>SHERLY MOSESSIAN (May 27, 2025 07:10 PDT)</small> Sherly Mosessian Ph.D Chief Scientific Officer Date: <u>May 27, 2025</u>	By <u>Firmato digitalmente da: Lorenzo Stefano</u> <u>Maffioli</u> Name: <u>Organizzazione: I.R.S.T./03154520401</u> Unità organizzativa: <u>DIREZIONE GENERALE</u> Title: <u>Data: 20/05/2025 12:37:54</u> Date: _____

## Appendix 1 to Exhibit A-5

### FAPI WORK REQUEST

#### GENERAL INFORMATION – please fill out below

SPONSOR NAME AND ADDRESS	
INSTITUTION NAME AND ADDRESS	Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRCCS IRST S.r.l. - Meldola (FC)
TYPE OF INSTITUTION (university clinic, research centre, municipal hospital, private centre, other)	Research Centre
PLACE OF RADIOPHARMACEUTICAL PRODUCTION (hospital, external supplier, other)	Radiopharmacy/Nuclear Medicine Department IRST Dino Amadori Via Piero Maroncelli, 40 - Meldola, 47014 (FC) Italy
POINT OF CONTACT NAME	Dr. Paola Caroli
POINT OF CONTACT ADDRESS	Nuclear Medicine Department IRST Dino Amadori Via Piero Maroncelli, 40 - Meldola, 47014 (FC) Italy
POINT OF CONTACT EMAIL	<a href="mailto:paola.caroli@irst.emr.it">paola.caroli@irst.emr.it</a> <a href="mailto:valentina.diiorio@irst.emr.it">valentina.diiorio@irst.emr.it</a>
FAPI COMPOUND OF INTEREST (e.g. FAPI-74 or FAPI-46, etc.)	FAPI-46
DIAGNOSTIC OR THERAPEUTIC USE	Diagnostic use
CHEMISTRY, PRECLINICAL OR CLINICAL USE	Clinical use
FOR CLINICAL- SPECIFY INDICATION(s)	Solid tumors
FOR CLINICAL- SPECIFY ANTICIPATED PATIENT #	50
LIST OF LOCATIONS	Nuclear Medicine IRST Dino Amadori The radiopharmaceutical will be produced in Radiopharmacy IRST, that is nearby Nuclear Medicine IRST.
CONTACT DETAILS FOR CONTRACTS TEAM	
MATERIAL SHIP TO ADDRESS	Radiopharmacy IRST Dino Amadori Via Piero Maroncelli, 40 - Meldola, 47014 (FC) Italy
MATERIAL SHIP TO CONTACT INFO (NAME, EMAIL, PHONE)	Valentina Di Iorio; <a href="mailto:valentina.diiorio@irst.emr.it">valentina.diiorio@irst.emr.it</a> ; +390543739930
ACCOUNTS PAYABLE CONTACT INFO (NAME, EMAIL, PHONE)	
TARGET STUDY INITIATION DATE	26/05/2023
TARGET COMPLETION DATE	study ongoing

Please separately list the information requested below for each proposed study.

#### PROJECT TITLE:

68Ga-FAPI-46 PET-CT for molecular assessment of fibroblast activation and risk assessment in solid tumors.

#### DESCRIPTION OF WORK:

##### 1. Introduction of Research Subject:

The growth and spread of the tumor is determined not only by the tumor cells but also by the non-malignant constituents of the malignant lesion, which contributes to what is commonly referred to as the “tumor microenvironment”. In particular, a subpopulation of fibroblasts called cancer-associated fibroblasts are involved in tumor growth, migration and progression. Therefore, these cells represent an attractive target for both diagnosis and anticancer therapy. A distinctive feature of cancer-associated fibroblasts is the expression of the fibroblast activating protein (FAP), a type II membrane-bound glycoprotein. FAP plays a role in normal developmental processes during embryogenesis and in tissue







# FAPI-0080 - MTA - A-5\_Draft\_13MAY25\_signed IRST

Final Audit Report

2025-05-27

Created:	2025-05-27
By:	Sangeeta Kalra (sangeeta.kalra@sofie.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAAAtvoxHVqnRiJQv5V9PMFxzIxEcQLxaceX

## "FAPI-0080 - MTA - A-5\_Draft\_13MAY25\_signedIRST" History

-  Document digitally presigned by Lorenzo Stefano Maffioli (lorenzo.maffioli@irst.emr.it)  
2025-05-20 - 10:37:54 AM GMT
-  Document created by Sangeeta Kalra (sangeeta.kalra@sofie.com)  
2025-05-27 - 2:08:18 PM GMT
-  Document emailed to SHERLY MOSESSIAN (sherly.mosessian@sofie.com) for signature  
2025-05-27 - 2:08:46 PM GMT
-  Email viewed by SHERLY MOSESSIAN (sherly.mosessian@sofie.com)  
2025-05-27 - 2:10:09 PM GMT
-  Document e-signed by SHERLY MOSESSIAN (sherly.mosessian@sofie.com)  
Signature Date: 2025-05-27 - 2:10:25 PM GMT - Time Source: server
-  Agreement completed.  
2025-05-27 - 2:10:25 PM GMT